Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 373

1.

Genome-wide cell-free DNA fragmentation in patients with cancer.

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.

Nature. 2019 Jun;570(7761):385-389. doi: 10.1038/s41586-019-1272-6. Epub 2019 May 29.

PMID:
31142840
3.

Effect of chromoendoscopy in the proximal colon on colorectal neoplasia detection in Lynch syndrome: a multicenter randomized controlled trial.

Haanstra JF, Dekker E, Cats A, Nagengast FM, Hardwick JC, Vanhoutvin SA, de Vos Tot Nederveen Cappel WH, Vasen HF, Kleibeuker JH, Koornstra JJ.

Gastrointest Endosc. 2019 Apr 24. pii: S0016-5107(19)31650-5. doi: 10.1016/j.gie.2019.04.227. [Epub ahead of print]

PMID:
31028782
4.

Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.

Rijkmans EC, Marijnen CAM, van Triest B, Ketelaars M, Cats A, Inderson A, van den Ende RPJ, Laman MS, Kerkhof EM, Nout RA.

Radiother Oncol. 2019 Apr;133:176-182. doi: 10.1016/j.radonc.2019.01.034. Epub 2019 Feb 18.

PMID:
30935576
5.

No clear role for angiogenesis inhibitors in first-line therapy for stomach cancer.

Cats A.

Lancet Oncol. 2019 Mar;20(3):323-324. doi: 10.1016/S1470-2045(18)30892-1. Epub 2019 Feb 1. No abstract available.

PMID:
30718071
6.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply.

Henricks LM, Lunenburg CATC, Cats A, Mathijssen RHJ, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2019 Feb;20(2):e67. doi: 10.1016/S1470-2045(19)30010-5. No abstract available.

PMID:
30712800
7.

High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.

Rigter LS, Spaander MCW, Aleman BMP, Bisseling TM, Moons LM, Cats A, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, Snaebjornsson P, Kuipers EJ, Bruno MJ, Dekker E, Meijer GA, de Boer JP, van Leeuwen FE, van Leerdam ME.

Cancer. 2019 Mar 15;125(6):990-999. doi: 10.1002/cncr.31903. Epub 2018 Dec 18.

8.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
9.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.

PMID:
30485432
10.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
11.

Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial.

Claassen YHM, Hartgrink HH, de Steur WO, Dikken JL, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Kranenbarg WMM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Gastric Cancer. 2019 Mar;22(2):369-376. doi: 10.1007/s10120-018-0875-1. Epub 2018 Sep 20.

12.

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M.

BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2.

13.

Adjuvant therapy in resectable gastric cancer-the CRITICS trial - Authors' reply.

Cats A, Sikorska K, Verheij M.

Lancet Oncol. 2018 Jul;19(7):e331. doi: 10.1016/S1470-2045(18)30436-4. Epub 2018 Jun 29. No abstract available.

PMID:
30084374
14.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769. doi: 10.1111/bcp.13719. Epub 2018 Sep 25.

15.

Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results from the CRITICS Trial.

Claassen YHM, van Amelsfoort RM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Boot H, Trip AK, Jansen EPM, Kranenbarg EM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Ann Surg. 2018 Jul 10. doi: 10.1097/SLA.0000000000002940. [Epub ahead of print]

PMID:
29995679
16.

Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial.

Claassen YHM, van Sandick JW, Hartgrink HH, Dikken JL, De Steur WO, van Grieken NCT, Boot H, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenbarg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Br J Surg. 2018 May;105(6):728-735. doi: 10.1002/bjs.10773.

PMID:
29652082
17.

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators.

Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9.

PMID:
29650363
18.

Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.

Claassen YHM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenbarg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Eur J Surg Oncol. 2018 May;44(5):613-619. doi: 10.1016/j.ejso.2018.02.004. Epub 2018 Feb 9.

PMID:
29503129
19.

Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit.

Schouwenburg MG, Busweiler LAD, Beck N, Henneman D, Amodio S, van Berge Henegouwen MI, Cats A, van Hillegersberg R, van Sandick JW, Wijnhoven BPL, Wouters MWJ, Nieuwenhuijzen GAP; Dutch Upper GI Cancer Audit group.

Eur J Surg Oncol. 2018 Apr;44(4):532-538. doi: 10.1016/j.ejso.2018.01.008. Epub 2018 Jan 12.

PMID:
29439836
20.

Evaluation of clinical and endoscopic toxicity after external beam radiotherapy and endorectal brachytherapy in elderly patients with rectal cancer treated in the HERBERT study.

Rijkmans EC, van Triest B, Nout RA, Kerkhof EM, Buijsen J, Rozema T, Franssen JH, Velema LA, Laman MS, Cats A, Marijnen CAM.

Radiother Oncol. 2018 Mar;126(3):417-423. doi: 10.1016/j.radonc.2017.12.023. Epub 2018 Feb 3.

PMID:
29398154
21.

Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer.

van der Kaaij RT, van Kessel JP, van Dieren JM, Snaebjornsson P, Balagué O, van Coevorden F, van der Kolk LE, Sikorska K, Cats A, van Sandick JW.

Br J Surg. 2018 Jan;105(2):e176-e182. doi: 10.1002/bjs.10754.

PMID:
29341148
22.

Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility.

Weren RDA, van der Post RS, Vogelaar IP, van Krieken JH, Spruijt L, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, Oliveira C, Kamping EJ, Schackert HK, Ranzani GN, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Cats A, Bjørnevoll I, Hoogerbrugge N, Ligtenberg MJL.

J Med Genet. 2018 Oct;55(10):669-674. doi: 10.1136/jmedgenet-2017-104962. Epub 2018 Jan 12.

23.

Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study.

Beck N, Busweiler LAD, Schouwenburg MG, Fiocco M, Cats A, Voncken FEM, Wijnhoven BPL, van Berge Henegouwen MI, Wouters MWJM, van Sandick JW; Dutch Upper GI Cancer Audit (DUCA) Group and the Dutch Gastric Cancer Perioperative Therapy Study group.

Eur J Surg Oncol. 2018 Feb;44(2):260-267. doi: 10.1016/j.ejso.2017.11.023. Epub 2017 Dec 13.

PMID:
29273212
24.

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM.

Ann Oncol. 2017 Dec 1;28(12):2915-2922. doi: 10.1093/annonc/mdx411.

PMID:
29045513
25.

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.

Henricks LM, Siemerink EJM, Rosing H, Meijer J, Goorden SMI, Polstra AM, Zoetekouw L, Cats A, Schellens JHM, van Kuilenburg ABP.

Int J Cancer. 2018 Jan 15;142(2):424-430. doi: 10.1002/ijc.31065. Epub 2017 Sep 30.

26.

Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial.

Claassen YHM, de Steur WO, Hartgrink HH, Dikken JL, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Kranenbarg WMM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Ann Surg. 2018 Dec;268(6):1008-1013. doi: 10.1097/SLA.0000000000002444.

PMID:
28817437
27.

Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.

van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW.

JMIR Res Protoc. 2017 Jul 13;6(7):e136. doi: 10.2196/resprot.7790.

28.

Incidence of small bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy.

Haanstra JF, Al-Toma A, Dekker E, Vanhoutvin SALW, Nagengast FM, Mathus-Vliegen EM, van Leerdam ME, de Vos Tot Nederveen Cappel WH, Veenendaal RA, Cats A, Sanduleanu S, Vasen HFA, Kleibeuker JH, Koornstra JJ.

Endosc Int Open. 2017 Jul;5(7):E622-E626. doi: 10.1055/s-0043-111723. Epub 2017 Jul 6.

29.

Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria.

van der Post RS, van Dieren J, Grelack A, Hoogerbrugge N, van der Kolk LE, Snaebjornsson P, Lansdorp-Vogelaar I, van Krieken JH, Bisseling TM, Cats A.

Gastrointest Endosc. 2018 Feb;87(2):397-404.e2. doi: 10.1016/j.gie.2017.04.016. Epub 2017 Apr 25.

PMID:
28455161
30.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM.

Br J Cancer. 2017 May 23;116(11):1415-1424. doi: 10.1038/bjc.2017.94. Epub 2017 Apr 20.

31.

Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study.

Rijkmans EC, Cats A, Nout RA, van den Bongard DHJG, Ketelaars M, Buijsen J, Rozema T, Franssen JH, Velema LA, van Triest B, Marijnen CAM.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):908-917. doi: 10.1016/j.ijrobp.2017.01.033. Epub 2017 Jan 20.

PMID:
28366579
32.

The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.

van der Kaaij RT, Snaebjornsson P, Voncken FE, van Dieren JM, Jansen EP, Sikorska K, Cats A, van Sandick JW.

Eur J Cancer. 2017 May;76:27-35. doi: 10.1016/j.ejca.2017.01.031. Epub 2017 Mar 3.

PMID:
28262585
33.

Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.

Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roesink JM, Raemaekers JM, van der Maazen RW, Cats A, Bleiker EM, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, Te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME.

BMC Cancer. 2017 Feb 7;17(1):112. doi: 10.1186/s12885-017-3089-8.

34.

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

Meulendijks D, Rozeman EA, Cats A, Sikorska K, Joerger M, Deenen MJ, Beijnen JH, Schellens JHM.

Pharmacogenomics J. 2017 Oct;17(5):441-451. doi: 10.1038/tpj.2016.81. Epub 2016 Dec 20.

PMID:
27995989
35.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T.

Dig Liver Dis. 2016 Nov;48(11):1283-1289. doi: 10.1016/j.dld.2016.08.112. Epub 2016 Aug 20.

PMID:
27590840
36.

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

Meulendijks D, Cats A, Beijnen JH, Schellens JH.

Cancer Treat Rev. 2016 Nov;50:23-34. doi: 10.1016/j.ctrv.2016.08.002. Epub 2016 Aug 13. Review.

PMID:
27589829
37.

Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.

Meulendijks D, Henricks LM, van Kuilenburg AB, Jacobs BA, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, Schellens JH.

Cancer Chemother Pharmacol. 2016 Oct;78(4):875-80. doi: 10.1007/s00280-016-3137-0. Epub 2016 Aug 20.

PMID:
27544765
38.

Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.

Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema AD, Steeghs N.

Clin Pharmacokinet. 2017 Mar;56(3):287-292. doi: 10.1007/s40262-016-0439-7.

PMID:
27435281
39.

Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy.

Bosch SL, Vermeer TA, West NP, Swellengrebel HA, Marijnen CA, Cats A, Verhoef C, van Lijnschoten I, de Wilt JH, Rutten HJ, Nagtegaal ID.

Histopathology. 2016 Nov;69(5):839-848. doi: 10.1111/his.13008. Epub 2016 Jul 26.

40.

Reply to T. Magnes et al.

Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Jul 10;34(20):2434-5. doi: 10.1200/JCO.2016.67.4374. Epub 2016 May 9. No abstract available.

PMID:
27161961
41.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH.

Br J Clin Pharmacol. 2016 Sep;82(3):706-16. doi: 10.1111/bcp.13007. Epub 2016 Jun 3.

42.

Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry.

Vasen HF, Velthuizen ME, Kleibeuker JH, Menko FH, Nagengast FM, Cats A, van der Meulen-de Jong AE, Breuning MH, Roukema AJ, van Leeuwen-Cornelisse I, de Vos Tot Nederveen Cappel WH, Wijnen JT.

Fam Cancer. 2016 Jul;15(3):429-35. doi: 10.1007/s10689-016-9897-1.

43.

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.

Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, Schellens JH, Grootscholten C, Tesselaar ME, Cats A.

Cancer. 2016 May 1;122(9):1434-43. doi: 10.1002/cncr.29864. Epub 2016 Mar 11.

44.

Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.

Tomasoa NB, Meulendijks D, Nijkamp J, Cats A, Dewit L.

Acta Oncol. 2016 Jun;55(6):760-6. doi: 10.3109/0284186X.2015.1124141. Epub 2016 Feb 15.

PMID:
26878244
45.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH.

Int J Cancer. 2016 Jun 1;138(11):2752-61. doi: 10.1002/ijc.30014. Epub 2016 Feb 19.

46.

The Effect of Supplementary Bone-Suppressed Chest Radiographs on the Assessment of a Variety of Common Pulmonary Abnormalities: Results of an Observer Study.

Schalekamp S, Karssemeijer N, Cats AM, De Hoop B, Geurts BH, Berger-Hartog O, van Ginneken B, Schaefer-Prokop CM.

J Thorac Imaging. 2016 Mar;31(2):119-25. doi: 10.1097/RTI.0000000000000195.

PMID:
26783697
47.

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

Meulendijks D, van Hasselt JGC, Huitema ADR, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JHM.

Eur J Cancer. 2016 Feb;54:120-130. doi: 10.1016/j.ejca.2015.10.013. Epub 2016 Jan 4.

PMID:
26761784
48.

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).

Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S.

Br J Cancer. 2015 Dec 22;113(12):1747. doi: 10.1038/bjc.2015.458. No abstract available.

49.

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, Tesselaar ME, Schellens JH, Cats A.

Invest New Drugs. 2016 Feb;34(1):119-28. doi: 10.1007/s10637-015-0309-4. Epub 2015 Dec 8.

PMID:
26643663
50.

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH.

Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23. Review.

PMID:
26603945

Supplemental Content

Support Center